PET Imaging CCR2 in Lung Inflammation

Description

The primary objective of this study is to assess the lung distribution of the Positron Emission Tomography (PET) imaging radiotracer Cu-DOTA-ECL1i, which binds to the specific population inflammatory cells, in patients with fibrotic lung diseases. This objective includes sub-studies to assess radiotracer distribution in the lung, the reproducibility of PET scans and the relationship of the scan to distribution of inflammatory cells in human lung tissue. The overall goal is to assess the potential of the radiotracer to track inflammatory cells in lung diseases.

Conditions

Lung Inflammation

Talk to us

Study Overview

On this page

Study Details

Study overview

The primary objective of this study is to assess the lung distribution of the Positron Emission Tomography (PET) imaging radiotracer Cu-DOTA-ECL1i, which binds to the specific population inflammatory cells, in patients with fibrotic lung diseases. This objective includes sub-studies to assess radiotracer distribution in the lung, the reproducibility of PET scans and the relationship of the scan to distribution of inflammatory cells in human lung tissue. The overall goal is to assess the potential of the radiotracer to track inflammatory cells in lung diseases.

PET Imaging CCR2 in Lung Inflammation

PET Imaging CCR2 in Lung Inflammation

Condition
Lung Inflammation
Intervention / Treatment

-

Contacts and Locations

Saint Louis

Washington University School of Medicine, Saint Louis, Missouri, United States, 63110

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Men or women 21 years of age or older who have never smoked or current smokers who smoked at least 10 cigarettes per day (1/2 pack) and have smoked at least 100 cigarettes (5 packs) over the past month.
  • * Screening FEV1 and FVC \> 80% of predicted
  • * Capable of lying still and supine within the PET/CT and PET/MR scanner for \~1 hour and follow instructions for breathing protocol during the CT portion
  • * No illicit drug use or other inhaled drug use (including pharmacologic agents, recreational agents, or illicit drugs) within the past year
  • * No known history of cardiac, pulmonary, hepatic or renal disease or diabetes
  • * No history of claustrophobia or other preventing condition that has previously or would interfere with completion of protocol specified imaging sessions
  • * Able to comprehend and willing to follow instructions for the study procedures as called for by the protocol
  • * BMI ≤ 35
  • * Currently enrolled in another study using an investigational drug
  • * Pregnancy (confirmed by urine pregnancy test)
  • * Active symptoms or history of cardiac, pulmonary, hepatic or renal disease or diabetes
  • * Currently taking any prescription medications
  • * Presence of an implanted device that is incompatible with CT or MRI scanning
  • * Creatinine \> 1.30 mg/dL, AST \> 50 Units/L, ALT \> 55 Units/L, or total bilirubin \> 1.2 mg/dL

Ages Eligible for Study

21 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Washington University School of Medicine,

Steven Brody, MD, PRINCIPAL_INVESTIGATOR, Washington University School of Medicine

Study Record Dates

2026-08-31